FDA clears blood test to aid evaluation for Alzheimer's disease
29 points by dabinat 3 hours ago | 5 comments
brandonb 58 minutes ago
This Alzheimer's blood test, PrecivityAD2, is based on the p-tau217 biomarker.
replyIn one recent study, people very high p-tau217 had a 38% chance of progressing to cognitive impairment within 5 years vs 12% for those with low levels. The current tests cost about $200-300, so they're not unreasonable as a screening test.
vintermann 7 minutes ago
That sounds pretty expensive for me for a test with that low accuracy, especially when there's not much you can do different if it comes back high vs. coming back low.
reply
Good as in scientifically proven. Not speculative fantasy.
As someone with family affected by this disease, it’s a very personal choice whether you want to know or not, but I wish people understood that there are many things you can do with it, particularly for those who will be there for you if/when it hits.
Taking care of a loved one with this disease is extremely hard, and it’s even harder when they haven’t had any chance to prepare for this eventuality. Stuff like written records of your history (health, life, etc.), clear powers of attorney, and so on.
It also makes things much easier for healthcare professionals.
https://www.nih.gov/news-events/news-releases/combination-he...
> Early detection of Alzheimer’s disease is important since the first treatments capable of slowing the progression of the neurodegenerative disease recently became available to patients, and these drugs are more effective when started sooner rather than later.